The Product

IscAlert™ is a biomedical sensor system that measures the partial gas pressure of carbon dioxide (pCO2) in tissue local to sensor placement.

The problem today is that injury to most organs are detected too late. Unfortunately, existing detection solutions simply cannot provide the early, accurate and real time monitoring required by surgeons and healthcare organisations.

Ischemia is highly preventable if it can be detected early.

IscAlert™ is a ground-breaking and patented solution with a numbers of benefits

  • IscAlert™ addresses a largely unmet medical need as a user friendly, fast, robust and cost effective real time monitoring device of ischemia.

  • IscAlert™ fits well into current medical practice by giving improved patient outcome and therefore substantially reduces healthcare costs by lowering the need for e.g. intensive care.

  • IscAlert™ is a direct and realtime method for measuring ischemia.

A Lifesaver Biomarker

Carbon dioxide (CO2) is an end-metabolic product of all cells in all tissues. The human body keeps the tissue levels of CO2 in a narrow and very well controlled range. Any change of the tissue CO2 (or) level is considered pathologic, indicating either insufficient blood or oxygen to the tissue (ischemia), or excess oxygen to the tissue (hyperventilation).

The Unique Sensor Technology

Sensocure is the owner of a unique proprietary technology for detecting the tissue pCO2 level. The tissue pCO2 level may change due to critical perfusion, respiration or metabolic conditions. The Sensocure pCO2 technology gives basis for a row of products for early detection of either critical local or systemic conditions with high mortality and considerable cost to the healthcare providers.

IscAlert™

IscAlert™ is a proven miniature sensor technology easily injected into organs to accurately monitor tissue carbon dioxide (pCO2) in real time, giving clinicians ample time to take appropriate actions to prevent or minimize tissue/organ damage.

Unlike other approaches, IscAlert™ provides continuous, real-time readings, detects ischemia in all tissues, and is easy and cost-effective to adopt.